Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration. The French drugmaker said ...

Paris: Sanofi has received fast track designation from the US Food and Drug Administration (FDA) for SAR446597, a one-time ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration ...